

Evolve in contract negotiations with the US government for funding to advance nootkatone against Zika

1 June 2017 – Evolve (SIX: EVE) confirms a media report stating that the Company is negotiating a sole-source contract with the US Biomedical Advanced Research and Development Authority (BARDA) to advance the development and EPA registration of Evolve's nootkatone product to help in the fight against the mosquitoes that transmit Zika virus. No further details can be provided at this time.

- ends -

About Evolve

Evolve solves the supply chain issues of nature through a 21st century mix of biotechnology and brewing. We develop, make and sell natural ingredients that provide significant benefits to people in daily life, but whose supply chain issues have limited their use until now. Our flagship ingredients are stevia, nootkatone and resveratrol, but we work on many more, both on our own behalf and with others. To make our world sustainable requires nature and technology to work together as one, and our aim is to play a (small) part in achieving this transformation. We operate internationally. For more information see www.evolve.com. Questions about our approach? Have a look at our [video](#).

About nootkatone

Nootkatone is a citrus ingredient that is characteristically associated with grapefruit. It can be extracted in minute quantities from the skin of grapefruit or the bark of the Alaska yellow cedar (also known as the *Nootka cypress*), or produced on an industrial scale from brewing via yeast fermentation. Nootkatone is being tested against a variety of biting and nuisance pests, notably the ticks that are responsible for spreading Lyme disease, but also the mosquitoes contributing to the spread of Zika, chikungunya, dengue and West Nile viruses, as well as head lice, bed bugs, and other biting insects.

About Zika virus

Zika virus disease (Zika) is a disease caused by Zika virus that is spread to people primarily through the bite of an infected *Aedes* species mosquito. The most common symptoms of Zika are fever, rash, joint pain, and conjunctivitis (red eyes). Because the symptoms of Zika are similar to those of many other diseases, many cases may not have been recognised.

Contact Details

Neil Goldsmith, CEO
neilg@evolva.com
+ 41 61 485 2005

Stephan Herrera, Media
stephanh@evolva.com
+ 1 415 794 4005

Paul Verbraeken, IR
paulv@evolva.com
+ 41 61 485 20 35

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.